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Abstract
Background: In this study, we investigated the anti-obesity and anti-hyperlipidemic mechanisms of lambertianic
acid (LA) isolated from Pinus koraiensis leaves and the ethanol extract of Pinus koraiensis leaves (EPK), both in vitro
and in vivo.
Methods: Differentiated 3T3L-1 cells were treated with EPK (25 or 50 μg/mL) or LA (200 μM) and analyzed by
western blotting or RT-PCR. In vitro, lipid accumulation of adipocytes was observed using Oil-Red-O staining and
triglyceride analysis. The contribution of AMPK to anti-obesity activity was assessed by siRNA-mediated AMPK
knockdown. After AMPK silencing, expression of AMPK was observed by western blotting. To confirm the in vitro
activity, an animal study was conducted by administering a normal diet, HFD, and EPK for 6 weeks. Obesity-related
physiological parameters and protein levels were measured.
Results: LA induced the expression of p-AMPK and inhibited PPARγ, C/EBP α, adiponectin, FAS, SREBP-1, and
HMGCR expression. EPK containing LA significantly decreased lipid accumulation and triglyceride levels in the
differentiated 3 T3-L1 cells. EPK treatment suppressed the expression of adipogenic transcription factors, FABP,
GPDH, and cholesterol-synthesis-related factors in the differentiated 3 T3-L1 cells. EPK increased the expression of
p-AMPK. The effects of EPK were reversed on inhibiting AMPK by using AMPK siRNA and compound C. In vivo
analysis showed that body weight gain, serum triglyceride, total cholesterol, LDL cholesterol and AI value in the
EPK treatment group were lower than those in the HFD control group. EPK induced the expression of p-AMPK
and inhibited PPARγ in liver and adipose tissue.
Conclusions: Overall, the results suggest that EPK containing LA exerts significant anti-obesity and cholesterol-
lowering effects by activating AMPK.
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Background
Obesity is a complex multifactorial chronic disease
characterized by excess body fat and is associated
with concurrent diseases that reduce life expectancy,
including cardiovascular disease, stroke, hyperlipid-
emia, fatty liver, and diabetes [1, 2]. Obesity caused
by hypertrophy of adipose tissue as well as adipose
tissue hyperplasia triggers the differentiation of prea-
dipocytes into adipocytes [3]. Adipocyte differentiation
is regulated by crucial transcription factors such as
peroxisome proliferator-activated receptor-γ (PPARγ)
and CCAAT/enhancer-binding proteins α (C/EBPα).
These transcription factors control the expression of
many adipogenic proteins [4–7]. Several studies have
reported that Sterol regulatory element-binding pro-
tein 1 (SREBP-1) is a transcription factor that regu-
lates adipogenesis, cellular cholesterol, and cholesterol
synthesis proteins, such as 3-hydroxy-3-methylgluta-
ryl-coenzyme A reductase (HMGCR), in 3 T3-L1 adi-
pocytes [8–10]. Adenosine monophosphate-activated
protein kinase (AMPK) is a key enzyme in energy
metabolism and is involved in regulation of glucose
levels and lipid uptake. AMPK is expressed in a num-
ber of tissues, including adipose tissue, the liver, skel-
etal muscle, the heart, pancreatic beta cells, and brain
cells [11, 12]. AMPK is phosphorylated and inacti-
vates metabolic enzymes involved in fatty acid and
cholesterol syntheses [13–15]. AMPK also provides an
upstream signal of PPARγ/CEBPα and suppresses dif-
ferentiation of preadipocytes into adipocytes [16–18].
Activation of AMPK decreases cellular cholesterol
and fatty acids, such as SREBP-1 and HMGCR [19,
20]. Recently, the identification of a natural com-
pound that can exert anti-obesity effects with fewer
side effects than currently available prescription medi-
cations is attracting attention [4]. One such com-
pound is P. koraiensis (Korean nut pine), which is
native to Korea, Japan, China, and Eastern Russia.
The main chemicals in essential oil from P. koraiensis
leaves (EOPK) are camphene, D-limonene, borneol, α-
pinene, 3-carene, 4-carene, β-phellandrene, and fencyl
[21]. Our previous research has shown that EOPK has
anti-hyperlipidemic [21], anti-diabetic [22], anti-
obesity [23] and anti-cancer effects [24]. P. koraiensis
seed oil has been investigated to inhibition of lipid
metabolism in rats and mice [25, 26]. However, the
biological and biochemical effects of the ethanol ex-
tract of P. koraiensis (EPK) and its main compounds
have not yet been proven. The EPK is easier to ex-
tract than EOPK. In addition, EPKs are convenient
and easy to use. The purpose of this study is to in-
vestigate the anti-adipogenic effect of EPK on 3T3L-1




The leaves of P. koraiensis were used same materials
with our previous study and the details were described
in our previous published study [24].
Preparation of EPK
The EPK was prepared using the hydrodistillation method
with dried and pulverized P. koraiensis leaves. In order to
increase the extraction efficiency, P. koraiensis leaves and
young stems under 1 cm in diameter were cut into 2–3
cm sections. P. koraiensis leaves were obtained from the
agricultural corporation Beaksongyounlim (Gangwondo,
Korea) and authenticated by the Department of Oriental
Medicine Biotechnology at Kyung Hee University. Dried
and pulverized leaves (1 kg) were immersed in 50 % etha-
nol (10 L) and distilled. The reflux distillation was contin-
ued for 10 h at 45 °C and was repeated twice. The EPK
was prepared under reduced pressure to obtain 30 Brix.
Extraction and isolation of LA
The EPK was partitioned with EtOAc / distilled water
(1:1). The water layer was suspended and partitioned with
n-butanol / distilled water. Coulum chromatography of
the EtOAc fraction showing anti-hyperlipidemic activity,
over silica gel using an n-hexan-EtOAc-chloroform-
MeOH mixture with increasing polarity, yielded 15
fractions. 15 fractions were confirmed with thin layer
chromatography. Among these fractions, fr. 6 showed
distinct and vivid red-purple color by TLC. Also the fr. 6
showed the most potent anti-hyperlipidemic aciticity. LA
was obtained by an additional purification step from fr. 6.
The structure of LA was identified by 1H-nuclear
magnetic resonance (NMR) and 13C-nuclear magnetic
resonance (NMR). (Additional file 1: Figure S1)
Cell culture assay
3T3L-1 preadipocytes were purchased from Korean Cell
Line Bank (KCLB). The cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) with 4500 mg/L D-
glucose, 10 % fetal bovine serum (FBS), 2 μM L-glutamine
and penicillin/streptomycin (WelGene, Daegu, South
Korea) in a humidified atmosphere of 5 % CO2 at 37 °C.
Cytotoxicity assay
Cytotoxicity of EPK was evaluated with the 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium brom-
ide (MTT) (Sigma Aldrich, St Louis, MO) assay. The
cells were seeded at a density of 1 × 104cells per well in
a 96-well plate, cultured for 24 h, and then treated with
various concentrations of EPK. After 24 h incubation,
50 μL of MTT solution (1 mg/mL) was added to each
well and incubated for 2 h at 37 °C in darkness. The vi-
able cell number was correlated with the production of
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formazan, which was dissolved with dimethyl sulfoxide
(DMSO), and optical density (O.D.) was measured with
a microplate reader (Sunrise, TECAN, Mannedorf,
Switzerland) at 570 nm. Cell viability was calculated by
the following equation: Cell viability (%) = [O.D.(EPK)-
O.D.(blank)]/[O.D(control)-O.D.(blank)] × 100.
Differentiation induction and Oil-Red-O staining
The preadipocyte 3 T3-L1 cells were plated on 6-well plates
on day 0 and incubated until confluency was achieved. For
adipocyte differentiation, the confluent cells were treated
with 1 μM dexamethasone, 1 μg/mL insulin, and 0.5 mM
IBMX for 2 days, and the medium was replaced by fresh
normal medium containing only 1 μg/mL insulin for 2
days. On day 2, the differentiated adipocyte cells were cul-
tured in the presence or absence of EPK (25 or 50 μg/mL)
for 6 days. The medium was changed every 2 days. The
cells were fixed with 2 % paraformaldehyde, washed twice
with PBS, and finally stained with Oil-Red-O. The cellular
lipid retained Oil-Red-O in isopropanol and adipocyte
expression was estimated by measuring O.D. with a micro-
plate reader (Sunrise, TECAN, Mannedorf, Switzerland) at
510 nm.
RT-PCR analysis
The preadipocyte 3 T3-L1 cells were plated onto 6-well
plates on day 0 and incubated until confluency was
achieved. For adipocyte differentiation, the confluent
cells were treated with 1 μM dexamethasone, 1 μg/mL
insulin, and 0.5 mM IBMX for 2 days, and the medium
was replaced by fresh normal medium containing only 1
μg/mL insulin for 2 days. On day 2, the differentiated
adipocyte cells were cultured in the presence or absence
of EPK (25 or 50 μg/mL) for 6 days. The total RNA was
extracted by using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
cDNA was synthesized from 1 μg of total RNA and sub-
jected to PCR reaction by using a SuperScript One-Step
reverse transcription-PCR (RT-PCR) kit (Invitrogen,
Carlsbad, CA, USA). The PCR conditions were as
follows: 30 cycles of 94 °C for 30 s, 57 °C for 30 s, and
72 °C for 30 s. The primer sequences have been provided
in Table 1 (Additional file 2: Table S1). PCR products
were run on 2 % agarose gels and then stained with eth-
idium bromide. Stained bands were visualized under UV
light and photographed.
Western blot analysis
On day 2, the differentiated adipocyte cells were cul-
tured in the presence or absence of EPK (25 or 50 μg/
mL) or LA (200 μM) for 6 days. Cell were lysed in RIPA
buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 %
NP-40, 0.25 % deoxycholic acid-Na, 1 M EDTA, 1 mM
Na3VO4, 1 mM NaF, and protease-inhibitor cocktail).
The proteins in the samples were quantified using Bio-
Rad DC protein assay kit II (Bio-Rad, Hercules, CA),
separated by electrophoresis on 8 to 10 % SDS-PAGE
gels, and electrotransferred onto a Hybond ECL transfer
membrane (Amersham Pharmacia, Piscataway, NJ). The
membranes were blocked in 3 % nonfat skim milk and
probed with primary antibodies for PPARγ (Novus,
Littleton, CO, USA), C/EBPα (Cell Signaling Tech.,
Danvers, MA, USA), p-AMPK (Cell Signaling Tech.,
MA, USA), AMPK (Cell Signaling Tech., MA, USA),
adiponectin (Cell Signaling Tech., MA, USA), FABP
(Cell Signaling Tech., Danvers, MA, USA), HMGCR
(Bioss Antibodies, MA, USA), SREBP-1 (Sigma, St.
Louis, MO, USA), or β-actin (Sigma, St. Louis, MO,
USA) overnight. Subsequently, they were exposed to
horseradish peroxidase (HRP)-conjugated secondary
anti-mouse or rabbit antibodies. Protein expression
was examined by using the enhanced chemiluminescence
(ECL) system (Amersham Pharmacia, Piscataway, NJ).
AMPK gene silencing
AMPK small interfering RNA (siRNA) was purchased
from Cell Signaling. A control siRNA was purchased
from Santa Cruz Biotechnology. To transfect the siRNA,
3 T3-L1 cells were plated at a density of 4 × 105 cells
per well in a 6-well plate. The cells were transfected
using 100 nM of AMPK siRNA with INTERFERin (Poly
plus, France) for 48 h. After treatment, the cells were
confirmed by western blot.
HPLC analysis
In order to analyze the compounds from EPK, standards
for the compounds were run on HICHROM HPLC col-
umns (5 μM, 250 × 4.6 mm, Hichrom Ltd.) using a high
HPLC system (Agilent Technologies, CA). The binary
mobile phase consisted of 35 % to 100 % methanol-
tetrahydrofuran solvent (99.5:0.5, v/v). The solvent flow
rate was 1.0 mL/min and ambient temperature was set at
30 °C. UV detection was at a wavelength of 260 nm.
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Animals
Male Sprague–Dawley rats (age, 4 weeks) were purchased
from Hyo-Chang Science (Daegu, Korea). The rats were
maintained under specific pathogen-free conditions with a
12 h light–dark cycle, 55 % humidity, and 22 ± 2 °C. All
animal procedures were approved by the institutional
Animal Care and Use Committee (IACUC) of Kyungsung
University (Permit Number: 2011-13A), and performed in
accordance with the Policy of the Ethical Committee of
Ministry of Health and Welfare, Korea.
Experimental design and EPK treatment
Forty rats were divided into four groups (10 rats per
group): normal group (low fat diet), control group
(HFD), and two EPK-treated groups consuming HFD.
Rats were fed the low fat diet or the HFD for 6 weeks.
HFD composition has been described in Table 2. For
EPK treatment dissolved in 4 % tween 80/normal saline
was orally administered once daily to the rats at doses
of 100 and 200 mg/kg for 6 weeks from the first day of
HFD-feeding, whereas PBS was orally administered to
the rats in the control group.
Preparation of rat serum
Whole blood was collected from rats by the cardiac
puncture method and serum was isolated by centrifuga-
tion at 3000 rpm for 10 min.
Measurement of serum lipids level
Total cholesterol level was measured by using a total
cholesterol assay kit (AM 202-K, Asan Pharm Co.,
Seoul, Korea) based on Richmond’s method [27]. Pipet
0.3 mL of the enzymatic cholesterol reagent into a test
tube. Add either 20 μL of serum or glycerol standard.
Mix well and incubate at 37 °C for at 30 min. Measure
the absorbancesof samples and standard at 550 nm.
Triglyceride level was measured by a triglyceride
assay kit (AM 157S-K, Asan Pharm Co., Seoul, Korea)
based on McGowan’s method [28]. Pipet 0.3 mL of the
enzymatic triglyceride reagent into a test tube. Add ei-
ther 20 μL of serum or glycerol standard. Mix well
and incubate at 37 °C for at 30 min. Measure the
absorbancesof samples and standard at 500 nm.
Measurement of serum HDL and LDL levels
The levels of high-density lipoprotein (HDL) and low-
density lipoprotein (LDL) in serum were measured using
the Roche Cobas C-111 analyzer (Roche-Diagnostics,
Indianapolis, IN, USA): Atherosclerosis index (AI) was
calculated by employing the following equation: AI = (total
cholesterol − HDL cholesterol)/HDL cholesterol.
Measurement of body weight, retroperitoneal fat, and
epididymal fat
The body weight of rats in normal (N), control (C), and
EPK (100 and 200 mg/kg)-treated groups was monitored
once a week for 6 weeks. The retroperitoneal and epididy-
mal fat was also removed from EPK (100 and 200 mg/kg)-
treated rats on the last day of animal study and weighed.
Immunohistochemical staining
For histopathological examination, paraffin sections (4 μM)
from dissected liver and adipose tissues were stained with
hematoxylin and eosin. Immunohistochemical staining of
PPARγ (Novus, Littleton, CO, USA) and p-AMPK (Cell
signaling Tech., MA, USA) was performed using the indir-
ect avidin/biotin-enhanced horseradish peroxidase method.
Antigen retrieval was performed after dewaxing and dehy-
dration of the tissue sections by microwaving for 10 min in
10 mM citrate buffer. Sections were cooled to room
temperature, treated with 3 % hydrogen peroxide in metha-
nol for 10 min, and blocked with 6 % horse serum for 30
min at room temperature in a humidity chamber. The sec-
tions were then incubated with primary antibody against
PPARγ (diluted 1: 200; Novus, Littleton, CO, USA) or p-
AMPK (diluted 1: 150; Cell Signaling) at 4 °C overnight in a
humidity chamber. The sections were washed in PBS and
incubated with secondary antibody (biotinylated goat anti-
rabbit antibody; diluted 1: 150; Vector Laboratories,
Burlingame, CA, USA) for 30 min in the humidity cham-
ber. After further washes, the antibodies were detected
with the Vector ABC complex/horseradish peroxidase
(HRP) kit (Vector Laboratories, Burlingame, CA, USA)
and color developed with 3,3′-diaminobenzidine tetrahy-
drochloride. For semiquantitation, ten photomicrographs
(200×) were taken with a CCD camera, avoiding gross
necrotic areas.
Measurement of adipocyte size
Images were acquired using an Axio Imager. Adipocyte size
in adipoxe tissue was analyzed using Image J (National
Institutes of Health, Bethesda, MD) software.
Table 2 Composition of normal and HFD
Ingredient Normal (low-fat) diet (%) HFD (%)
Casein 20.0 20.0
DL-methionine 0.3 0.3
Corn starch 15.0 15.0
Sucrose 50.0 34.5
Fiber 5.0 5.0
Corn oil 5.0 -
AIN-mineral mixture 3.5 3.5
AIN-vitamin mixture 1.0 1.0
Choline bitartate 0.2 0.2
Beef tallow - 20.5
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Statistical analysis
All data are shown as mean ± SD. In vitro experiment data
were analyzed by Student’s t-test. In vivo experiment data
were calculated by analysis of variance (ANOVA) followed
by Duncan’s multiple range test. A P value of less than 0.05
was considered statistically significant. Means in the same
column with different superscript letters (a, b, c, d, e and f)
are significantly different (P < 0.05) between groups.
Results
LA as an active ingredient in EPK
Through activity-guided fractionation (Additional file 1:
Figure S1), we identified LA (Fig. 1a) from P. koraiensis
needles as a novel anti-hyperlipidemic compound for use in
increasing LDLR. The effects of LA on adipocyte differenti-
ation and adipogenesis were assessed by western blotting
and Oil-red-O staining. As shown in Fig. 1d, LA signifi-
cantly decreased the expression of PPARγ, C/EBPα, related
target genes (adiponectin, FAS, SREBP-1 and HMGCR)
and increased the expression of p-AMPK, while no change
was observed in its total protein expression. Furthermore,
LA reduced lipid accumulation in 3 T3-L1 adipocytes by
32 % compared with that seen for the control group (Fig. 1b
and c). To analyze LA in EPK, LA content was determined
by HPLC. As shown in Fig. 1e, EPK contained LA. The
peak showed that the retention time of LA was 59 min.
The EPK included 98.7 μg/mg of LA.
Effect of EPK containing LA on fat accumulation in 3 T3-L1
adipocytes
Because in vitro study of adipose cells is easier in
established cell lines [29], we examined the cytotoxic
effect of EPK in 3 T3-L1 preadipocytes. Cells were
treated with various concentrations of EPK (0, 3.125,
6.25, 12.5, 25, 50, 100, and 200 μg/mL) for 24 h, after
which cell viability was evaluated by the MTT assay.
As shown in Fig. 2a, EPK had no significant effect on
the viability of 3 T3-L1 cells [23]. To investigate
whether EPK alters the cellular differentiation in adi-
pocytes, Oil-Red-O staining and triglyceride level ana-
lysis was performed in 3 T3-L1 cells [30]. 3 T3-L1
adipocytes were exposed to EPK for 6 days. The dif-
ferentiated 3 T3-L1 adipocytes showed significantly
increased fat accumulation (Fig. 2b and c) as com-
pared to the control cells. EPK at concentrations of
25 or 50 μg/mL reduced the cellular lipid droplets in
3 T3-L1 adipocytes by 49 and 68.8 %, respectively,
compared to the untreated control adipocytes. More-
over, EPK treatment reduced the level of serum tri-
glycerides in 3 T3-L1 cells in a dose-dependent
manner (21.8 and 33.7 % at concentrations of 25 and
50 μg/mL, respectively), compared to that in preadi-
pocytes (59.92 %; Fig. 2d).
Effect of EPK on adipogenesis in 3 T3-L1 preadipocytes
Adipocyte differentiation is the process of regulating a
set of gene-expression events [31]. The well-studied
PPARγ, C/EBPα, glycerol-3-phospate dehydrogenase
(GPDH) and fatty acid-binding protein (FABP) are
crucial transcription factor and promote adipogenesis
[32]. To elucidate the regulatory mechanisms responsible
for the anti-adipogenesis effect of EPK, the mRNA expres-
sion levels of PPARγ, C/EBPα, and GPDH were investi-
gated by RT-PCR. EPK remarkably suppressed PPARγ, C/
EBPα, and GPDH in 3 T3-L1 cells (Fig. 3a). In addition,
the protein expression of adipogenic factors was examined
using western blotting. As shown in Fig. 3b, the protein
levels of PPARγ, C/EBPα, adiponectin SREBP-1, HMGCR,
and FABP reduced in a concentration-dependent manner.
AMPK is an important regulator of preadipocyte differen-
tiation and adipogenesis. EPK at concentrations of 25 or
50 μg/mL increased p-AMPK, while no change was ob-
served in its total protein expression (Fig. 3b). To further
investigate the role of AMPK in preadipocyte differenti-
ation and cholesterol synthesis and to confirm whether
EPK modulates adipogenesis and cholesterol through
AMPK, we used AMPK siRNA or the AMPK inhibitor
compound C. We detected the expression of C/EBPα,
PPARγ, FAS, SREBP-1, and HMGCR after cells were
treated with the AMPK inhibitor compound C or AMPK
siRNA. As shown in Fig. 3c and d, AMPK siRNA signifi-
cantly reduced AMPK protein expression. The p-AMPK
induced by EPK was abrogated by pretreatment with com-
pound C or AMPK siRNA. PPARγ, FAS, SREPBP-1, and
HMGCR, downstream of AMPK, were decreased by EPK
treatment and these effects were reversed in the presence
of compound C or AMPK siRNA. In addition, the lipid
content of fat droplets was also restored in the presence of
compound C (Fig. 3e).
Effect of EPK on the body weight of HFD-fed rats
The body weights of normal group (N), control group (C),
and EPK-treated groups were monitored once a week for
6 weeks. As shown in Fig. 4a, the body weights of the
HFD-fed control group were significantly greater at 2
weeks after feeding, compared to those for the normal low
fat group. In contrast, the body weight gain was dose de-
pendently abrogated in EPK-treated groups, from the 3rd
week of treatment with EPK. In addition, 6 weeks after
treatment, body weights increased to 331.4 ± 2.8 g in the
HFD-fed control group (normal group, 281.6 ± 1.7 g).
However, EPK significantly suppressed the body weights
to 309.5 ± 1.8 g and 303.7 ± 2.0 g, respectively, at doses of
100 mg/kg and 200 mg/kg.
Effects of EPK on abdominal fat weight of HFD-fed rats
The retroperitoneal and epididymal fat weights were mea-
sured to test whether the body weight normalization by
Lee et al. BMC Complementary and Alternative Medicine  (2016) 16:51 Page 5 of 13
EPK in HFD-fed rats was associated with reduction of fat
content in the body. In this study, HFD significantly in-
creased the retroperitoneal fat weight to 18.3 ± 2.91 mg/g
from 6.21 ± 1.26 mg/kg body weight. In contrast, EPK
decreased the retroperitoneal fat weight to 15.7 ± 1.86 and
12.7 ± 1.43 mg/g at doses of 100 and 200 mg/kg, respect-
ively, compared to the HFD-fed control group (Fig. 4b).
Likewise, epididymal fat weight also increased in the
HFD-fed rats compared to the weight in the normal
group. Oral administration of EPK decreased epididymal
fat pad weight by 10.9 ± 1.85 and 8.52 ± 1.96 mg/g at
doses of 100 and 200 mg/kg, respectively (Fig. 4b). More-
over, HFD-fed rats showed a significant increase (53.1 %,
P < 0.01) in the cell size of epididymal adipose tissues
compared to normal adipose tissues, whereas EPK-treated
groups showed significantly decreased hypertrophic adi-
pocyte formation (Fig. 4c). The expression of p-AMPK in
both adipose and liver tissues was increased by EPK in the
HFD compared to the control group. In addition, the
expression of PPARγ in both adipose and liver tissue was
lower in the EPK treated group than in the control group
(Fig. 4d and e).
Fig. 1 Effects of LA on adipogenesis in 3 T3-L1 preadipocytes. a Chemical structure of LA. b 3 T3-L1 preadipocytes were treated with
various concentrations of LA during differentiation. On day 8, the differentiated cells were stained with Oil-red-O dye and visualized under
inverted microscopy at 100× magnification. c The cellular lipid retained Oil-Red-O in isopropanol and adipocyte expression was estimated
by measuring O.D. with a microplate reader (Sunrise, TECAN, Mannedorf, Switzerland) at 510 nm. ### 0.001 < P (compared to preadipocte)
and ** P < 0.01 (compared to adipocyte). Data are expressed as mean ± SD. d Total protein prepared from LA-treated 3 T3-L1 (preadipocytes or adipocyte)
cells were subjected to western blot analysis for AMPK, p-AMPK, PPARγ, C/EBPα, adiponectin, FAS, SREBP-1, HMGCR, and β-actin. e HPLC analysis of LA in
EPK. Preadipocyte (P)
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Fig. 2 Effect of EPK on the differentiation of 3 T3-L1 adipocytes. a 3 T3-L1 cells were treated with various concentrations of EPK (0, 3.125, 6.25,
12.5, 25, 50, 100, and 200 μg/mL) for 24 h; then, the cell viability was evaluated by the MTT assay. b 3 T3-L1 preadipocytes were treated with
various concentrations of EPK during differentiation. On day 8, the differentiated cells were stained with Oil-red-O dye and visualized under
inverted microscopy at 100× magnification. c The cellular lipid retained Oil-Red-O in isopropanol and adipocyte expression was estimated by
measuring O.D. with a microplate reader (Sunrise, TECAN, Mannedorf, Switzerland) at 510 nm. ### P < 0.001 (compared to preadipocyte) and ***
P < 0.001 (compared to adipocyte). d Level of serumtriglyceride. ## P < 0.01 (compared to preadipocyte) and * P < 0.05 (compared to adipocyte).
Data are expressed as mean ± SD. Preadipocyte (P)
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Fig. 3 Effect of EPK on adipogenesis in 3 T3-L1 preadipocytes. 3 T3-L1 preadipocytes were incubated in medium containing insulin (1.0 μg/mL)
with or without the indicated concentrations of EPK or CC. a Total RNA was extracted from 3 T3-L1cells treated with EPK and used for RT-PCR
analysis of PPARγ, C/EBPα, GPDH, and β-actin. b Total proteins prepared from EPK-treated 3 T3-L1 cells were subjected to western blot analysis for
AMPK, p-AMPK, PPARγ, C/EBPα, adiponectin, FABP, SREBP-1, HMGCR, and β-actin. c 3 T3-L1 cells were transfected with AMPK-siRNA for 48 h and
treated with or without EPK (50 μg/mL) for 24 h and subjected to western blot analysis for AMPK, p-AMPK, PPARγ, SREBP-1, and β-actin. d Total
proteins prepared from EPK (50 μg/mL) or CC (2 μM)-treated 3 T3-L1 cells for 6 h were subjected to western blot analysis for AMPK, p-AMPK,
PPARγ, FAS, SREBP-1, HMGCR, and β-actin. e Cells were fixed and stained with Oil-Red-O. The Oil-Red-O-stained adipocytes were photographed at
100× magnification under a microscope. Preadipocyte (P), compound C (CC)
Lee et al. BMC Complementary and Alternative Medicine  (2016) 16:51 Page 8 of 13
Effects of EPK on serum lipid and cholesterol levels in
HFD-fed rats
The consumption of the HFD significantly increased trigly-
ceride levels in the control group, as compared to those in
the normal low fat group (Fig. 5a). EPK treatment de-
creased the level of serum triglyceride from 131.8 ± 18.2 to
109.3 ± 11.5 and 94.2 ± 8.43 mg/dL at 100 and 200 mg/kg,
respectively (Fig. 5a). Additionally, the consumption of
HFD significantly increased serum total cholesterol com-
pared to that in the normal low fat group, while EPK
significantly reduced the level of total cholesterol in a dose-
dependent manner (Fig. 5b). The intake of the HFD signifi-
cantly decreased the level of HDL but increased the level of
LDL compared to those for the normal group (Fig. 5c,
Fig. 4 Effect of EPK on body and abdominal fat weights of HFD-fed rats. Rats fed a HFD were orally treated with or without EPK daily for 6 consecutive
weeks. a Body weights of rats. b Abdominal fat and retroperitoneal and epididymal fat from rats treated with or without EPK (100 and 200 mg/kg)
were removed and weighed. c Average size of adipocytes measured in 5 different fields. ###P < 0.001 (compared to the normal), **P < 0.01 and ***P <
0.001 (compared to the control group). d Representative picture of immunohistochemical staining for PPARγ and p-AMPK in adipocyte tissue sections.
###P < 0.001 (compared to normal group), **P < 0.01 and ***P < 0.001 (compared to control group). e Representative picture of immunohistochemical
staining for PPARγ and p-AMPK in liver tissue sections. ##P < 0.01 (compared to normal group), **P < 0.01 and *** P < 0.001 (compared to control
group). Data are expressed as mean ± SD. Values with the different superscript letters indicate statistical significance (P < 0.05) between
groups by Duncan’s multiple range test. Normal group (N), control group (C)
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control). However, EPK did not have a significant impact
on LDL levels but elevated HDL levels in a dose-dependent
manner compared to those seen for the HFD control group
(Fig. 5c). EPK treatment significantly decreased the AI value
in a dose-dependent manner compared to the AI deter-
mined for the HFD control (Fig. 5d).
Effects of EPK on hepatic triglyceride and cholesterol
levels in HFD-fed rats
The consumption of HFD significantly increased hep-
atic triglyceride (Fig. 5e) and hepatic cholesterol levels
(Fig. 5f ), as compared to those in the normal low fat
group. Oral treatment with EPK reduced triglyceride
levels in the liver in a dose-dependent manner (24.4 ±
2.47 and 21.2 ± 1.88 mg/g at doses of 100 and 200
mg/kg, respectively), compared to those for the con-
trol group (29.8 ± 3.25 mg/g tissue) (Fig. 5e). In
addition, EPK administration significantly lowered
hepatic cholesterol levels in the liver from 16.9 ± 2.18
mg/g in the HFD control group to 12.6 ± 1.42 and
10.4 ± 1.59 mg/g at 100 and 200 mg/kg, respectively
(Fig. 5f ).
Fig. 5 Effects of EPK on serum lipid and cholesterol levels and on hepatic triglyceride and cholesterol. a Triglyceride levels were measured with a
triglyceride assay kit (AM157S-K, Asan PharmCo., Seoul, Korea). b Total cholesterol levels were measured by using a total cholesterol assay kit
(AM202-K, Asan PharmCo., Seoul, Korea). c The levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) in serum were measured
using the Cobas c 111 analyzer (Roche-Diagnostics, Indianapolis, IN, USA). d AI was calculated by employing the following equation: AI = (total
cholesterol − HDL cholesterol)/HDL cholesterol. e The levels of triglyceride in liver were measured with the Biochemistry Analyzer. f The levels of
total cholesterol in the liver were measured with the Biochemistry Analyzer. Data are expressed as mean ± SD. Values with the different superscript
letters indicate statistical significance (P < 0.05) between groups by Duncan’s multiple range test. Normal group (N), control group (C)
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Discussion
This study provides the first direct evidence of the anti-
obesity effects of EPK and its component LA, while
providing insight into the regulatory mechanisms
underlying those effects in rats with HFD-induced
obesity. Our findings show that EPK efficaciously in-
hibits adipocyte differentiation and adipogenesis in 3
T3-L1 adipocytes and in rats with HFD-induced obesity
by activating AMPK. In recent years, EOPK has been
reported to demonstrate anti-cancer, anti-obesity, and
anti-hypolipidemic effects [21, 23, 24]. EPK is easier to
extract than EOPK. There are significant differences
between EPK and EOPK with respect to their compo-
nents and extraction cost of the two extracts. Moreover,
EPK is convenient and easy to use.
Adipogenesis is a cellular differentiation process in
which the preadipocytes are transformed into differ-
entiated adipocytes [31] and accumulate lipids [33].
Therefore, controlling adipocyte differentiation is im-
portant. AMPK agonists and PPARγ antagonists ap-
pear to be involved in adipocyte differentiation and
thus can be potential drugs for the treatment of obes-
ity [34]. EPK suppressed fat accumulation and serum
triglyceride levels, decreased PPARγ, CEBPα, FABP,
and GPDH expression, and increased p-AMPK ex-
pression in the differentiated 3 T3-L1 adipocytes,
without any cytotoxic effect. Similarly, many natural
products, including green tomato extract [35], tiacre-
monone [4, 36, 37], and ursolic acid [38], suppress
adipogenesis and improve insulin sensitivity in vitro
and in vivo via AMPK and PPARγ signaling. More-
over, EPK in HFD-fed SD rats was found to reduce
body weight gain without loss of appetite (Additional
file 3: Figure S2). Loss of body weight is related to
decrease in fat pad mass as a result of reduction of
adipocyte size or triglyceride accumulation [39]. EPK
reduces the retroperitoneal and epididymal fat weight
as well as serum triglyceride levels compared to those
in HFD-fed rats. Our data suggest that EPK can pre-
vent obesity via inhibition of lipid metabolism, includ-
ing reduction of triglyceride levels.
Elevated cholesterol is a risk factor for obesity,
stroke, and heart disease, as well as diabetes [40].
Specifically, low levels of serum HDL cholesterol are
closely related to obesity [41]. EPK increased the level
of HDL cholesterol in a dose-dependent manner com-
pared to that in HFD-fed rats. Furthermore, EPK
decreased triglyceride and cholesterol levels, suggest-
ing that EPK regulates lipid metabolism, which was in
accordance with in vitro data. EPK inhibited SREBP-1
and HMGCR as the cholesterol related factor. Adipo-
genesis and cholesterol syntheses in adipocytes as well
as the liver, is regulated by SREBP-1 and HMGCR
[20, 42, 43]. Several natural compounds including
mevalonic acid [42], suppressed cholesterol levels in
vitro and in vivo through AMPK, SREBP-1, and
HMGCR in adipocytes, similary to our data. LA as an
active compound in EPK that is responsible for anti-
hyperlipidemic activity was identified by a bioactivity-
guided fractionation procedure. The active fractions
were characterized by reverse-phase HPLC and identi-
fied by mass spectrometry (Additional file 1: Figure
S1). LA is a bioactive diterpene and is known to have
anti-allergic effects [44]. LA inhibited fat accumula-
tion in adipocytes, induced p-AMPK expression, and
inhibited PPARγ expression. Further study is required
to verify the anti-obesity effects of LA in HFD-fed
animal models.
Conclusion
In summary, EPK decreased fat accumulation, serum
triglyceride levels, and PPARγ, CEBPα, FABP, GPDH,
SREBP-1, and HMGCR expression and induced p-
AMPK in the differentiated 3 T3-L1 adipocytes (Fig. 6).
Furthermore, EPK reduced the serum and hepatic
levels of triglyceride and total cholesterol in an in vivo
model. LA as an active compound in EPK inhibited
adipogenesis and controlled cholesterol synthesis re-
lated proteins level in 3 T3-L1 adipocytes via AMPK
Fig. 6 Effects of EPK and LA on anti-obesity in 3 T3-L1-
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pathways. Overall, our findings suggest the potential
of EPK as an anti-obesity and anti-hyperlipidemia
agent.
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